🔒 MEMBERS ONLY
UMAC Trade Breakdown & CEO Interview Analysis
Unusual Machines (NYSE American: UMAC)
July 13, 2026 | Marathon Money Research Team
Our Trade: Entry, Exit, and Current Position
First Interview Entry Price:
$11.00
Peak Price (June 2, 2026):
$33.00
We Sold Partial Position:
$30.00
Current Price (July 13, 2026):
$20.05
Gain on Sold Position:
+173% ($11 → $30)
Unrealized Loss on Held Portion:
-39% from Peak ($33 → $20.05)
Remaining Position Gain:
+82% ($11 → $20.05)
✓ EXECUTION WAS RIGHT: We took profits at $30 when momentum was extreme. That was textbook risk management. The stock peaked at $33 three days later. We got 91% of the way up before the pullback. That’s a win.
What Happened Since Our First Interview (March 2026)
The Catalyst Timeline:
April 20: Motor factory doubled capacity (700 → 1,500 units/day). Stock momentum building.
May 5: Announced $75M in strategic materials purchases. Signal: Real demand is being seen by management.
May 11: Upgrade Energy acquisition ($52M + $26M earnout). Battery platform play. Real capex commitment.
May 14: Q1 2026 earnings: Revenue $8.1M (+305% YoY). But operating loss expanded to $7.3M. Market reaction mixed.
May 28: Trump administration reportedly discussing federal funding for U.S. drone companies. Stock +60% that day. This was the peak catalyst.
June 2: Roth Capital raised price target to $40 (from $25). Stock peaked at $33. We sold at $30.
June 29: Added to Russell 2000 Index. Institutional visibility increase.
Now (July 13): Stock at $20.05 after 37% pullback from peak. Operating losses are the concern. Profitability timeline unclear.
What We Learned in the Second Interview
Manufacturing Reality Check
Allan confirmed motor capacity is actually being utilized. They’re not just building inventory. Real customer orders exist for the expanded capacity. That’s critical. Q1 showed $8.1M revenue. Next quarter likely $9-10M. But…
⚠️ THE PROBLEM: Operating losses are EXPANDING, not contracting. Q1 operating loss was $7.3M on $8.1M revenue. That’s a -89% operating margin. They’re burning cash on growth. He talked about “cash-flow positive by end of 2026.” That timeline now looks risky. We pressed him on it. No clear answer.
Defense Dollar Reality
The Drone Dominance Program is real. $90M component opportunity in 2026, $250M in 2027 — according to UMAC guidance. BUT: This is forecasted opportunity, not confirmed orders. There’s execution risk. If demand softens or government funding gets delayed, this story falls apart.
Stacy Wright’s Revenue Engine
New CRO. Transformed Rotor Riot from $1.7M annual to $2M quarterly. She’s the real revenue driver. That’s one person making this company’s top line happen. What happens if she leaves? Single-point-of-failure risk.
Lantronix Edge AI Partnership
Real technology moat. Integrated edge AI + drone flight control. This is years of competitive advantage IF they execute. Initial demonstrations in 12 months. This is long-term, not immediate revenue.
What Wall Street Is Saying
Consensus Rating:
Strong Buy (6 analysts)
Average Price Target (12 months):
$27.83 to $33.67
Roth Capital Target:
$40
Needham Target:
$30
High Estimate:
$42
Low Estimate:
$22-25
Current Price Upside (to avg target):
+38-68%
Downside Risk (to low estimate):
-10 to -22%
Translation: Wall Street is bullish. All Buy ratings. No Sells. But price targets have a huge spread ($22-42). That tells you: huge uncertainty. Execution risk is real.
Marathon Money’s Position & Strategy Going Forward
Sold Position at $30: ✓ CLOSED
Those shares are done. We locked in 173% gain. That capital is now deployed elsewhere or held in reserve for better risk/reward opportunities.
Held Position (25-35% of our UMAC allocation): HOLD, With Conditions
Why we’re holding the remaining position:
1. Supply constraints through 2027 are real. Customers are waiting in line. That’s a tailwind.
2. $90-250M defense opportunity is material. If even 20% comes through, revenue could hit $40M in 2027.
3. Lantronix partnership is a real competitive moat. Multi-year advantage if executed.
4. Russell 2000 inclusion brings institutional money. Momentum can continue.
5. Remaining position is already up 82% from entry. We’ve taken risk off the table.
BUT: We’re watching profitability closely. If Q2 2026 shows continued loss expansion and no path to positive gross margins, we exit the rest.
1. Supply constraints through 2027 are real. Customers are waiting in line. That’s a tailwind.
2. $90-250M defense opportunity is material. If even 20% comes through, revenue could hit $40M in 2027.
3. Lantronix partnership is a real competitive moat. Multi-year advantage if executed.
4. Russell 2000 inclusion brings institutional money. Momentum can continue.
5. Remaining position is already up 82% from entry. We’ve taken risk off the table.
BUT: We’re watching profitability closely. If Q2 2026 shows continued loss expansion and no path to positive gross margins, we exit the rest.
Exit Triggers (We Sell the Rest If):
1. Operating losses expand beyond $8M/quarter — Cash burn becomes unsustainable.
2. Q2 revenue misses $9M — Growth story breaks down.
3. Stacy Wright leaves — She’s the revenue engine. That’s a company risk.
4. Trump funding falls through — Stock would crater on narrative shift.
5. Customer concentration increases — If Powerus or PDW represent >40% of revenue, that’s a red flag.
6. Manufacturing execution stumbles — If they miss capacity targets in H2 2026.
2. Q2 revenue misses $9M — Growth story breaks down.
3. Stacy Wright leaves — She’s the revenue engine. That’s a company risk.
4. Trump funding falls through — Stock would crater on narrative shift.
5. Customer concentration increases — If Powerus or PDW represent >40% of revenue, that’s a red flag.
6. Manufacturing execution stumbles — If they miss capacity targets in H2 2026.
Entry Points for New Capital (If Stock Pulls Back Further):
$16-17: Represent strong support. Good risk/reward if we add.
$12-14: Would indicate broken thesis. Opportunity to rebuild position if story still intact.
$12-14: Would indicate broken thesis. Opportunity to rebuild position if story still intact.
Key Quotes from the Interview
On Profitability: “We’re targeting cash-flow positive by end of 2026. We see a path.” — Sounds more uncertain than when we last talked in March.
On Demand: “The market is supply-constrained through 2027. Demand exceeds supply.” — This is the real tailwind. If true, revenue compounds.
On Trump Funding: “Discussions are happening. Nothing signed yet.” — Stock rallied 60% on this. Expectations are now baked in. Disappointment risk is high.
Analyst Summary Report
| Metric | Status | Trend | Risk Level |
|---|---|---|---|
| Revenue Growth | $8.1M Q1 (+305% YoY) | ↑ Strong | Low (visible demand) |
| Operating Margin | -89% (loss $7.3M) | ↓ Deteriorating | High (expanding losses) |
| Path to Profitability | End of 2026 (target) | → Uncertain | High (timeline at risk) |
| Gross Margin | 32.8% (up from 24.3%) | ↑ Improving | Low (positive trend) |
| Cash Position | $222.9M (Q1) | → Stable | Low (12+ months runway) |
| Manufacturing Execution | Capacity doubled, on track | ↑ On schedule | Medium (unproven at scale) |
| Defense Opportunity | $90-250M opportunity | ↑ Real demand | Medium (timing uncertain) |
| Valuation | $20 stock = ~$500M market cap | → Fair (at $27-30 targets) | Medium (binary risk) |
Bottom Line Assessment:
RATING: ACCUMULATE ON WEAKNESS
UMAC is executing on revenue growth. Supply constraints are real. Defense opportunity is material. Lantronix partnership is a genuine competitive advantage. BUT: Operating losses are expanding faster than revenue growth. The profitability timeline is now at risk. Stock at $20 is fair based on fundamentals, not exciting. Stock at $25-30 assumes they hit profitability targets. Stock at $33+ assumes Trump funding materializes. All are possible. None are certain.
For our members: The remaining position is a growth play with 12-month timeframe. Watch Q2 earnings (due Aug 13). If revenue is $9M+ and gross margins stay 30%+, we hold and possibly add. If revenue misses or losses accelerate, we exit. This is not a “set it and forget it” stock. This requires active management.
UMAC is executing on revenue growth. Supply constraints are real. Defense opportunity is material. Lantronix partnership is a genuine competitive advantage. BUT: Operating losses are expanding faster than revenue growth. The profitability timeline is now at risk. Stock at $20 is fair based on fundamentals, not exciting. Stock at $25-30 assumes they hit profitability targets. Stock at $33+ assumes Trump funding materializes. All are possible. None are certain.
For our members: The remaining position is a growth play with 12-month timeframe. Watch Q2 earnings (due Aug 13). If revenue is $9M+ and gross margins stay 30%+, we hold and possibly add. If revenue misses or losses accelerate, we exit. This is not a “set it and forget it” stock. This requires active management.
Key Risks
Execution Risk: Manufacturing at scale is hard. They’ve hired 10x in 15 months. Culture, quality, and delivery can all break down.
Customer Concentration: Powerus ($30M), PDW ($3.75M), and a few others. What if one big customer cancels?
Regulatory Risk: Section 1709 (DJI ban) is driving demand. If policy changes or DJI passes review, tailwind disappears.
Shareholder Dilution: $307.8M raised on $11.2M revenue = 27x revenue. Lots of dilution. Stock could get back to $11 if thesis breaks.
Key Person Risk: Stacy Wright drives revenue. If she leaves, revenue growth stops. No bench strength visible.
Trump Funding Uncertainty: Stock priced in $30-40 assumes government funding materializes. If it doesn’t, -50% downside.
Customer Concentration: Powerus ($30M), PDW ($3.75M), and a few others. What if one big customer cancels?
Regulatory Risk: Section 1709 (DJI ban) is driving demand. If policy changes or DJI passes review, tailwind disappears.
Shareholder Dilution: $307.8M raised on $11.2M revenue = 27x revenue. Lots of dilution. Stock could get back to $11 if thesis breaks.
Key Person Risk: Stacy Wright drives revenue. If she leaves, revenue growth stops. No bench strength visible.
Trump Funding Uncertainty: Stock priced in $30-40 assumes government funding materializes. If it doesn’t, -50% downside.
What We’re Watching Next
Q2 2026 Earnings (Aug 13): Revenue target: $9M+. Gross margin target: 30%+. Operating loss target: <$7M. Beat/miss will determine holding.
Trump Funding Announcement: If official, stock could spike to $35-40. If delayed or denied, stock drops to $15-18.
Upgrade Energy Closing: Battery manufacturing integration. Earnout triggers on $10M revenue. Track progress.
Lantronix Demonstrations: First demos within 12 months (by March 2027). Real proof of technology moat.
Russell 2000 Index Effects: Passive inflows happening now. Watch if index funds are accumulating or if smart money is selling into the rally.
⚠️ IMPORTANT DISCLAIMER: This analysis is for Marathon Money members only. Not financial advice. UMAC is a high-risk micro-cap. Past performance does not guarantee future results. We have positions in UMAC and benefit from price appreciation. Do your own research. Consult a financial advisor. Only risk capital you can afford to lose entirely. Stock could go to $50 or $5. We do not recommend any specific action. This is educational analysis only.
Podcast: Play in new window | Download
Discover more from Marathon Money +
Subscribe to get the latest posts sent to your email.